1.Combining label-free quantitative proteomics and 2D-DIGE to identify the potential targets of Sini Decoction acting on myocardial infarction.
Fei FENG ; Weiyue ZHANG ; Yan CAO ; Diya LV ; Yifeng CHAI ; Dandan GUO ; Xiaofei CHEN
Chinese Journal of Natural Medicines (English Ed.) 2025;23(8):1016-1024
Sini Decoction (SNT) is a traditional formula recognized for its efficacy in warming the spleen and stomach and dispersing cold. However, elucidating the mechanism of action of SNT remains challenging due to its complex multiple components. This study utilized a synergistic approach combining two-dimensional fluorescence difference in gel electrophoresis (2D-DIGE)-based drug affinity responsive target stability (DARTS) with label-free quantitative proteomics techniques to identify the direct and indirect protein targets of SNT in myocardial infarction. The analysis identified 590 proteins, with 30 proteins showing significant upregulation and 51 proteins showing downregulation when comparing the SNT group with the model group. Through the integration of 2D-DIGE DARTS with proteomics data and pharmacological assessments, the findings indicate that protein disulfide-isomerase A3 (PDIA3) may serve as a potential protein target through which SNT provides protective effects on myocardial cells during myocardial infarction.
Myocardial Infarction/genetics*
;
Proteomics/methods*
;
Drugs, Chinese Herbal/chemistry*
;
Animals
;
Protein Disulfide-Isomerases/genetics*
;
Male
;
Two-Dimensional Difference Gel Electrophoresis/methods*
;
Humans
;
Rats
;
Rats, Sprague-Dawley
;
Electrophoresis, Gel, Two-Dimensional
2.Expert consensus on holistic integrative management of oral squamous cell carcinoma
Moyi SUN ; Zongxuan HE ; Haoyue XU ; Xiaoying LI ; Jie ZHANG ; Haijun LU ; Xiaohong ZHAN ; Dapeng HAO ; Shizhu BAI ; Wei GUO ; Zhangui TANG ; Guoxin REN ; Jian MENG ; Zhijun SUN ; Jichen LI ; Yue HE ; Chunjie LI ; Lizheng QIN ; Kai YANG ; Qing XI ; Lin KONG ; Bing HAN ; Lingxue BU ; Yuanyong FENG ; Kai SONG ; Hongyu HAN ; Jieying LI ; Qianwei NI ; Yun LI ; Juan CHAI ; Xiaochen YANG ; Man HU ; Mingjin XU ; Wei SHANG
Journal of Practical Stomatology 2025;41(4):437-449
Oral squamous cell carcinoma(OSCC)is a malignant lesion originating from the oral mucosal squamous epithelium,account-ing for over 80%of oral and maxillofacial malignancies.Key etiological factors include tobacco,alcohol abuse,and betel quid chewing.In China,its incidence has shown an overall upward trend,posing a significant threat to public health.OSCC exhibits high local invasive-ness,making early diagnosis critical for improving prognosis.Its clinical management requires close multidisciplinary collaboration among oral and maxillofacial surgery,head and neck surgery,radiation oncology,medical oncology,reconstructive surgery,radiology,patholo-gy,and nutritional support teams.Given the increasing disease burden of OSCC and rapid development of multidisciplinary collaborative models,an expert panel has formulated this integrated management consensus based on evidence-based medicine and extensive deliber-ation.Centered on the'Prevention-Screening-Diagnosis-Treatment-Rehabilitation'framework,the consensus provides comprehensive guidance for the entire disease course of OSCC patients,aiming to standardize clinical practice.
3.A multicenter clinical study on intramedullary vancomycin injection for preventing periprosthetic joint infection in total knee arthroplasty
Te LIU ; Jun FU ; Shiguang LAI ; Zhuo ZHANG ; Chi XU ; Lei GENG ; Yang LUO ; Peng REN ; Xin ZHI ; Quanbo JI ; Heng ZHANG ; Runkai ZHAO ; Haichao REN ; Ye TAO ; Qingyuan ZHENG ; Zeyu FENG ; Jianfeng YANG ; Yiming WANG ; Pengcheng LI ; Shuai LIU ; Wei CHAI ; Xiang LI ; Huiwu LI ; Xiaogang ZHANG ; Baochao JI ; Xianzhe LIU ; Xinzhan MAO ; Jianbing MA ; Xiangxiang SUN ; Jiying CHEN ; Yonggang ZHOU ; Jinliang WANG ; Weijun WANG ; Guoqiang ZHANG ; Ming NI
Chinese Journal of Orthopaedics 2025;45(12):803-811
Objective:To explore the safety and efficacy of intraosseous regional administration (IORA) of vancomycin for preventing infection in primary total knee arthroplasty (TKA).Methods:A total of 124 patients with knee osteoarthritis undergoing TKA between February 2024 and May 2024 at nine hospitals were enrolled. Preoperative infection prophylaxis involved either IORA (0.5 g vancomycin administered via intraosseous regional infusion before incision) or intravenous infusion (1 g vancomycin via peripheral vein). The IORA group included 15 males and 47 females with a median age of 66.5 years (range, 60.0-70.0 years), while the intravenous group included 14 males and 48 females with a median age of 66.0 years (range, 61.8-70.3 years) years. Intraoperative samples were collected including fat and synovium tissues after incision, before prosthesis placement, and after tourniquet release; distal femoral cancellous bone during femoral osteotomy; proximal tibial cancellous bone during tibial osteotomy; proximal intercondylar cancellous bone before prosthesis placement; and peripheral blood from non-infused arms at surgery initiation and after tourniquet release. Vancomycin concentrations were measured using liquid chromatography-tandem mass spectrometry. Vital sign changes were recorded from admission to 5~10 minutes post-IORA (IORA group) or post-incision (intravenous group). Follow-ups were conducted on postoperative day 1 and 3, and at 1 and 3 months, to document complications including IORA-related adverse events, periprosthetic joint infections, surgical site infections, red man syndrome, acute kidney injury, deep vein thrombosis and so on.Results:Vancomycin concentrations in bone, fat, and synovial tissue samples were significantly higher in the IORA group than in the intravenous group ( P<0.05), while vancomycin concentrations in blood samples were significantly lower in the IORA group than in the intravenous group ( P<0.05). Only 7.3%(41/558) of tissue samples in the IORA group had vancomycin concentrations below 2.0 μg/g (the minimum inhibitory concentration of vancomycin against coagulase-negative staphylococcus), compared to 59.3%(331/558) in the intravenous group (χ 2=11.285, P<0.001). In the intravenous group, 16.9%(21/124) of blood samples had vancomycin concentrations exceeding 15.0 mg/L (the threshold associated with a significantly increased risk of nephrotoxicity), while all concentrations in the IORA group were below this threshold, the difference was statistically significant (χ 2=22.943, P<0.001). There were no statistically significant difference ( P>0.05) in vital signs changes before and after vancomycin administration between the two groups. Two patients in the intravenous group experienced incision exudate, while no other related complications occurred in either group. Conclusions:Compared to the traditional intravenous infusion of 1 g vancomycin, intraosseous injection of a low dose (0.5 g) of vancomycin achieves higher local tissue concentrations in the knee joint with a lower incidence of adverse reactions and is safe for infection prophylaxis. Despite guidelines not recommending the routine use of vancomycin for preventing infection after primary TKA, intraosseous injection of 0.5 g vancomycin may be considered intraoperatively for primary TKA in the following scenarios: patients in medical institutions with a high prevalence of methicillin-resistant staphylococcus aureus (MRSA) infections, patients with potential preoperative MRSA colonization, or patients with cephalosporin allergy.
4.Effect of pegylated recombinant human granulocyte colony-stimulating factor on prevention of infections in children with acute lymphoblastic leukemia after chemotherapy
Lina CHAI ; Guoqi WANG ; Weihua REN ; Chen FENG
Chinese Journal of Nosocomiology 2025;35(21):3287-3292
OBJECTIVE To explore the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in prevention of infections in the children with acute lymphoblastic leukemia(ALL)after chemotherapy.METHODS The clinical data were retrospectively collected from the children with ALL who received vincristine+daunorubicin+pegaspargase+prednisone acetate(VDLP)induction chemo-therapy in pediatrics department of the First Medical Center of Chinese PLA General Hospital from Jan.2018 to Oct.2024,the children were respectively treated with PEG-rhG-CSF or recombinant human granulocyte colony-stimulating factor(rhG-CSF)during the chemotherapy.The incidence of grade Ⅲ/Ⅳ agranulocytosis,the lowest absolute value of neutrophils,duration of grade Ⅳ agranulocytosis,incidence of agranulocytosis accompanied by fever,incidence of infections,use of antibiotics and length of hospital stay were observed and compared between the two groups.RESULTS Totally 47 children with ALL were enrolled in the study and were assigned as the PEG-rhG-CSF group with 24 cases and the rhG-CSF group with 23 cases.There were no significant differences in the incidence rates of grade Ⅲ/Ⅳ agranulocytosis and musculoskeletal soreness between the two groups.The low-est absolute value of neutrophils of the PEG-rhG-CSF group[(0.88±0.87)× 109/L]was higher than that of the rhG-CSF group;the duration of grade Ⅳ agranulocytosis of the PEG-rhG-CSF group[2.50(0.00,6.50)d]was shorter than that of the rhG-CSF group;the incidence of agranulocytosis accompanied by fever(41.67%),inci-dence of infections(41.67%)and the percentage of children treated with antibiotics were lower in the PEG-rhG-CSF group than in the rhG-CSF group;the length of hospital stay of the PEG-rhG-CSF group was shorter than that of the rhG-CSF group;there were significant differences between the two groups(P<0.05).CONCLUSION The prophylactic use of PEG-rhG-CSF may raise the lowest value of neutrophils,shorten the duration of agranulo-cytosis,decrease the incidence of hospital-associated infections in the ALL children during the induction chemo-therapy,and reduce the use of antibiotics,with the safety favorable.
5.Application of 3D printing technology in bone graft fusion surgery for cervical spondylotic myelopathy
Lei TANG ; Qi WANG ; Zhi-yong CHAI ; Jun WANG ; Jing-ying GAI ; Yi-feng LIU
Journal of Regional Anatomy and Operative Surgery 2025;34(8):702-706
Objective To explore the clinical effect of 3D-printed interbody fusion cage applied in anterior cervical decompression and bone graft fusion for the treatment of cervical spondylotic myelopathy.Methods A total of 100 patients with cervical spondylotic myelopathy who underwent anterior cervical fusion surgery in our hospital from June 2020 to June 2023 were selected as the research subjects,they were randomly divided into the 3D group and the control group according to the random number table method,with 50 cases in each group.Patients in the 3D group were implanted with a 3D-printed interbody fusion cage which was made of microporous metal materials,while patients in the control group were implanted with intervertebral fusion cage which was made of polyetheretherketone material.The surgery-related indicators,cervical imaging parameters,cervical spinal cord function,cervical axial function and surgical complications of patients between the two groups were compared.Results There was no statistically significant difference in the operation time,intraoperative blood loss or length of hospital stay of patients between the two groups(P>0.05).The height of the cervical fusion segments and the Cobb angle of the fusion segments of patients in both groups at each time point after the operation were significantly increased compared with those before the operation(P<0.05).The height of the cervical fusion segments and the Cobb angle of the fusion segments of patients 1 month,3 months,and 6 months after the operation in the 3D group were all greater than those in the control group(P>0.05).The subjective symptom score and the total score of the Japanese orthopaedic association(JOA)of patients 6 months after the operation in the 3D group were higher than those in the control group(P<0.05).The cervical axial function of patients 6 months after the operation in the 3D group was better than that in the control group(P<0.05).The incidence of surgical complications in the 3D group was lower than that in the control group(P<0.05).Conclusion The use of 3D-printed interbody fusion cage during the anterior cervical decompression and bone graft fusion for patients with cervical spondylotic myelopathy can significantly improve the clinical symptoms of patients,achieve better cervical axial function,and have fewer complications.
6.Comparative Study of Seven New Dressings in Promoting Chronic Wound Healing in db/db Mice.
Qiuyun FENG ; Jia KE ; Danning QI ; Lei ZHOU ; Haiguang CHAI
Chinese Journal of Medical Instrumentation 2025;49(3):295-301
This study evaluated the healing-promoting effect and applicability of seven new dressings in chronic wounds. A chronic wound model was established using 48 db/db diabetic mice, which were randomly divided into 8 groups (control, polymer film, alginate, foam, hydrocolloid, hydrogel, carbon fiber, and silver dressing groups). Regular monitoring was conducted on the 5, 10, 15, and 20 days after surgery, and a comprehensive evaluation was performed based on healing rate, characteristic of histopathology, and semi-quantitative scoring. The results showed that, except for the polymer film dressing group, all other dressing groups had significantly better healing-promoting effect than the control group ( P<0.05), with the hydrocolloid, carbon fiber, and silver dressing groups demonstrated particularly outstanding efficacy. This study systematically compared the efficacy differences of seven dressings, and combined them with the adhesion, exudate volume and infection risks to provide a scientific basis for clinical dressing selection.
Animals
;
Mice
;
Wound Healing
;
Bandages
;
Male
;
Diabetes Mellitus, Experimental
;
Disease Models, Animal
7.Expert consensus on prognostic evaluation of cochlear implantation in hereditary hearing loss.
Xinyu SHI ; Xianbao CAO ; Renjie CHAI ; Suijun CHEN ; Juan FENG ; Ningyu FENG ; Xia GAO ; Lulu GUO ; Yuhe LIU ; Ling LU ; Lingyun MEI ; Xiaoyun QIAN ; Dongdong REN ; Haibo SHI ; Duoduo TAO ; Qin WANG ; Zhaoyan WANG ; Shuo WANG ; Wei WANG ; Ming XIA ; Hao XIONG ; Baicheng XU ; Kai XU ; Lei XU ; Hua YANG ; Jun YANG ; Pingli YANG ; Wei YUAN ; Dingjun ZHA ; Chunming ZHANG ; Hongzheng ZHANG ; Juan ZHANG ; Tianhong ZHANG ; Wenqi ZUO ; Wenyan LI ; Yongyi YUAN ; Jie ZHANG ; Yu ZHAO ; Fang ZHENG ; Yu SUN
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(9):798-808
Hearing loss is the most prevalent disabling disease. Cochlear implantation(CI) serves as the primary intervention for severe to profound hearing loss. This consensus systematically explores the value of genetic diagnosis in the pre-operative assessment and efficacy prognosis for CI. Drawing upon domestic and international research and clinical experience, it proposes an evidence-based medicine three-tiered prognostic classification system(Favorable, Marginal, Poor). The consensus focuses on common hereditary non-syndromic hearing loss(such as that caused by mutations in genes like GJB2, SLC26A4, OTOF, LOXHD1) and syndromic hereditary hearing loss(such as Jervell & Lange-Nielsen syndrome and Waardenburg syndrome), which are closely associated with congenital hearing loss, analyzing the impact of their pathological mechanisms on CI outcomes. The consensus provides recommendations based on multiple round of expert discussion and voting. It emphasizes that genetic diagnosis can optimize patient selection, predict prognosis, guide post-operative rehabilitation, offer stratified management strategies for patients with different genotypes, and advance the application of precision medicine in the field of CI.
Humans
;
Cochlear Implantation
;
Prognosis
;
Hearing Loss/surgery*
;
Consensus
;
Connexin 26
;
Mutation
;
Sulfate Transporters
;
Connexins/genetics*
8.Potential role of natural herbal monomer scutellarein in alleviating ischemic stroke
Jian-Yu WU ; Xue-Jie CHAI ; Yuan-Yuan YU ; Lin-Feng YANG
Acta Anatomica Sinica 2025;56(6):664-672
Objective To investigate the potential mechanisms by which the natural herbal monomer scutellarin alleviates ischemic stroke(IS)using network pharmacology and in vivo experimental validation.Methods Potential targets of scutellarin were predicted using SwissTargetPrediction and PharmMapper,and standardized via UniProt.IS-related differentially expressed genes(DEGs)were obtained from the GSE22255 dataset in the GEO database,with screening criteria of|log10FC|≥1 and P<0.05.Venny 2.1.0 analysis was used to identify overlapping targets.Protein-protein interaction(PPI)networks were constructed using STRING and visualized in cytoscape.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses were performed.Molecular docking was conducted using AutoDock Vina 1.5.6 to assess the binding affinity between scutellarin and hub targets.Middle cerebral artery occlusion(MCAO)mouse model was established and divided into sham,MCAO,and MCAO+scutellarin groups.Real-time PCR was used to detect mRNA expression of hub genes and phosphatidylinositol 3-kinase(PI3K)/Akt pathway components in the ischemic cortex.Results A total of 325 scutellarin targets and 2168 IS-related DEGs were identified,with 29 overlapping targets.GO analysis yielded 51 biological processes,5 cellular components,and 8 molecular functions.KEGG enrichment highlighted PI3K/Akt and metabolic pathways.PPI analysis identified Caspase-3,epidermal growth factor receptor(EGFR),prostaglandin-endoperoxide synthase 2(PTGS2),peroxisome proliferator activated receptor alpha(PPARA),and interleukin-2(IL-2)as key hub proteins.Molecular docking showed strong binding affinities between scutellarin and these proteins.Real-time PCR result confirmed that scutellarin modulated the expression of hub genes and activated the PI3K/Akt pathway.Conclusion In the MCAO mouse model,scutellarin exerts neuroprotective effects by modulating targets such as CASP3,EGFR,PTGS2,PPARA,and IL-2,and activating the PI3K/Akt signaling pathway,exhibiting multi-target and multi-pathway characteristics.
9.Modified probiotics and the related combinatorial therapeutics.
Luo ZHAO ; Mengya NIU ; Zilin MA ; Fengyun HE ; Xinxin LIU ; Xunwei GONG ; Zhanfei CHAI ; Ziqing WANG ; Qianhua FENG ; Lei WANG
Acta Pharmaceutica Sinica B 2025;15(5):2431-2453
Probiotics have shown excellent application prospects in preventing and treating many diseases. However, their sensitivity to the harsh environment in vivo always leads to a massive loss of viability and insufficient therapeutic effect. Fortunately, modified probiotics have emerged and provide multiple possibilities for their use in various diseases. Modification not only endows probiotics with extra capacity to resist severe environments but also gives them exogenous characteristics, such as prolonged retention time and improved therapeutic effects. Modified probiotics could combine with other therapies, which has opened up new avenues to enhance the efficacy of probiotic-based therapy. In this review, we have summarized the current physicochemical and biological modification strategies of probiotics. In addition, the progress of research on probiotic-based combination therapy has also been extensively reviewed, which contributes to the enhanced delivery of probiotics or other active constituents and provides new ideas for disease treatment, bioimaging, and diagnosis.
10.A DPAL method for the identification of the synergistic target of drugs.
Dongyao WANG ; Yuxiao TANG ; Na LI ; Chenghua WU ; Jianxin YANG ; Mengpu WU ; Feng LU ; Yifeng CHAI ; Chenqi LI ; Hui SHEN ; Xin DONG ; Changquan LING
Journal of Pharmaceutical Analysis 2025;15(11):101351-101351
Image 1.

Result Analysis
Print
Save
E-mail